Pelthos Therapeutics Inc. (PTHS) director Matthew Pauls executed a transaction involving the sale of 786 shares of the company's common stock on July 2, 2026. The total value of the disposition reached $20,561. The shares were liquidated at weighted average prices that fell within a range of $25.9959 to $27.3604. These sales were conducted in accordance with a Rule 10b5-1 trading plan that Pauls established on December 16, 2025. The specific objective of this automated selling program was to generate liquidity to cover estimated tax liabilities associated with the vesting of restricted stock units previously granted by Pelthos Therapeutics.
The execution of the sale involved two distinct pricing clusters. The first cluster consisted of 692 shares sold at a weighted average price of $25.9959 per share. These specific transactions were spread across multiple trades, with execution prices varying between $25.58 and $26.24. The second cluster involved the sale of an additional 94 shares at a higher weighted average price of $27.3604 per share. These trades occurred at prices ranging from $27.20 to $27.63. Following the completion of these transactions, Pauls retains a direct holding of 14,364 shares of Pelthos Therapeutics common stock.
The timing of this sale is notable given the recent performance of the stock. The shares have declined approximately 14% over the past week, trading at $24.60. This current price point sits below the range at which Pauls executed his sales. Market analysis suggests the stock may be undervalued at these current levels, though such assessments rely on proprietary research models. The company also recently reported its first-quarter 2026 earnings results, which fell significantly short of expectations. Pelthos Therapeutics reported an actual earnings per share of -3.09 USD, a stark contrast to the forecasted -0.51 USD. This discrepancy represents a surprise of -505.88%.
Despite the earnings miss, Pelthos Therapeutics experienced a structural change in its market classification. The company was added to the Russell 3000E Growth Benchmark, the Russell Microcap Index, and the Russell Microcap Growth Benchmark Index. This inclusion was part of the 2026 Russell indexes reconstitution and took effect on June 29. The reconstitution reflects the company's market capitalization ranking among the largest U.S. stocks. In a contrasting move, director Todd C. Davis acquired 35,948 shares for approximately $999,980, signaling a different perspective on the company's valuation. The stock closed at 24.60 USD, showing a gain of 1.11% during regular trading hours, followed by a decline of 0.81% in after-hours trading.